The recent paper on eye disorders associated with newer antiseizure drugs is an interesting work [1]. The authors tried to evaluate this association based on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) using a disproportionality analysis. We agree with the authors on the limited literature of adverse effects of newer antiseizure drugs [1]. Authors concluded that topiramate and lamotrigine were disproportionately associated with serious eye-related adverse events.
13
FEB
FEB
0